Pancreatic Cancer Research

ResearcherTel Aviv UniversityActive in the last 2 years

Talia Golan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5939-7012; OpenAlex author ID A5078820101. Sources: ClinicalTrials.gov.

Their work

Papers
62 (first author 1, last author 6)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
255
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 4 papers · 2018: 5 papers, 1 trial · 2019: 6 papers · 2020: 6 papers · 2021: 8 papers · 2022: 7 papers · 2023: 11 papers · 2024: 4 papers · 2025: 3 papers · 2026: 2 papers

Papers 50 of 62

  1. Histologic spectrum of BRCA-associated pancreatic ductal adenocarcinoma: A descriptive morphologic study. Co-author DOI 10.1016/j.humpath.2026.106201↗
  2. A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-3189↗
  3. A metabolic switch to the pentose-phosphate pathway induces radiation resistance in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2024.110606↗
  4. Elevated Carcinoembryonic Antigen Levels Predict Failure to Reach Surgery in Patients with Borderline Resectable Pancreatic Cancer Referred to Neoadjuvant Ther… Co-author DOI 10.1245/s10434-025-17433-3↗
  5. Pancreatic Cancer with Liver Oligometastases-Different Patterns of Disease Progression May Suggest Benefits of Surgical Resection. Co-author DOI 10.3390/jcm14155538↗
  6. Serum matrix metalloproteinase-7, Syndecan-1, and CA 19-9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.70144↗
  7. The benefit of pancreatic cancer surveillance in carriers of germline BRCA1/2 pathogenic variants. Co-author DOI 10.1002/cncr.35052↗
  8. Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8+ T cell activation and limit responsiveness to immunotherapy in mice. Co-author DOI 10.1038/s41467-024-50441-7↗
  9. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  10. Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival. Co-author DOI 10.1001/jamanetworkopen.2023.45013↗
  11. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic… Co-author DOI 10.1002/cam4.6621↗
  12. Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. Last author DOI 10.1002/cncr.34610↗
  13. Strategies for the Management of Patients with Pancreatic Cancer with PARP Inhibitors. Co-author DOI 10.1007/978-3-031-30065-3_8↗
  14. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Co-author DOI 10.1016/j.annonc.2023.08.009↗
  15. A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic te… Co-author DOI 10.1016/j.esmoop.2023.100881↗
  16. RBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05820-3↗
  17. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting. Last author DOI 10.1158/2159-8290.cd-22-0412↗
  18. POLQ inhibition elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma via cGAS/STING signaling. Co-author DOI 10.1172/jci165934↗
  19. Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake. Co-author DOI 10.1177/17588359231189127↗
  20. Pancreatic cancer outcome-local treatment with radiation using MRI-LINAC. Co-author DOI 10.3389/fonc.2023.1289919↗
  21. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  22. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations Co-author DOI 10.1016/j.gie.2021.12.001↗
  23. American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review… Co-author DOI 10.1016/j.gie.2021.12.002↗
  24. Loss of tumor suppressor WWOX accelerates pancreatic cancer development through promotion of TGFβ/BMP2 signaling. Co-author DOI 10.1038/s41419-022-05519-9↗
  25. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signali… Co-author DOI 10.1038/s41467-022-34081-3↗
  26. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic C… Last author DOI 10.1200/jco.21.01604↗
  27. Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.14309/ctg.0000000000000473↗
  28. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Pha… Last author DOI 10.1001/jamaoncol.2021.0006↗
  29. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Last author DOI 10.1016/j.annonc.2020.11.013↗
  30. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.01.220↗
  31. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  32. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Co-author DOI 10.1158/1535-7163.mct-20-0652↗
  33. AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition. Co-author DOI 10.1158/1541-7786.mcr-20-0985↗
  34. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. Co-author DOI 10.1200/jco.20.03238↗
  35. Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2021.7031↗
  36. Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control study. Co-author DOI 10.1002/pds.4993↗
  37. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Co-author DOI 10.1038/s41591-020-0880-x↗
  38. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1439↗
  39. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the… Co-author DOI 10.1200/jco.19.01890↗
  40. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08469-8↗
  41. ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy. Co-author DOI 10.1245/s10434-020-08495-6↗
  42. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Co-author DOI 10.1016/j.ccell.2018.12.010↗
  43. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1903387↗
  44. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Last author DOI 10.1093/annonc/mdz406↗
  45. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-3645↗
  46. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. Co-author DOI 10.1158/1541-7786.mcr-19-0589↗
  47. The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts. Co-author DOI 10.18632/oncotarget.27268↗
  48. Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG … Co-author DOI 10.1002/cncr.31058↗
  49. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adeno… Co-author DOI 10.1002/cncr.31218↗
  50. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models. Co-author DOI 10.1002/ijc.31292↗

Trials 1

  1. A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer Principal investigator NCT01676259↗

Closest collaborators

The 25 strongest of 255 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chani Stossel · 9 shared papers, 2017–2026 · strength 1.18
  2. Eileen Mary O'Reilly · 7 shared papers, 1 shared trial, 2017–2026 · strength 1.03
  3. Pascal R. Hammel · 6 shared papers, 2019–2023 · strength 0.85
  4. Steve Gallinger · 10 shared papers, 2014–2023 · strength 0.78
  5. Hedy Lee Kindler · 7 shared papers, 2017–2023 · strength 0.69
  6. Milind M. Javle · 5 shared papers, 2016–2026 · strength 0.65
  7. Yaacov Richard Lawrence · 5 shared papers, 2017–2025 · strength 0.62
  8. Jonathan Robert Brody · 5 shared papers, 2019–2023 · strength 0.61
  9. Salvatore Paiella · 5 shared papers, 2021–2024 · strength 0.60
  10. Raffaella Casolino · 4 shared papers, 2021–2023 · strength 0.59
  11. Andrew Victor Biankin · 4 shared papers, 2021–2023 · strength 0.59
  12. Ido Nachmany · 3 shared papers, 2020–2025 · strength 0.56
  13. Diane M. Simeone · 4 shared papers, 2021–2024 · strength 0.52
  14. Michael J. Hall · 4 shared papers, 2019–2023 · strength 0.49
  15. Ron Pery · 2 shared papers, 2025 · strength 0.46
  16. Nedaa Mahamid · 2 shared papers, 2025 · strength 0.46
  17. Niv Pencovich · 2 shared papers, 2025 · strength 0.46
  18. Arielle Jacover · 2 shared papers, 2025 · strength 0.46
  19. Ido Laish · 3 shared papers, 2022–2024 · strength 0.45
  20. Douglas L. Riegert‐Johnson · 3 shared papers, 2022–2023 · strength 0.44
  21. Teresa Mercade Macarulla · 5 shared papers, 2019–2022 · strength 0.44
  22. George Zogopoulos · 5 shared papers, 2019–2024 · strength 0.44
  23. Ben Boursi · 3 shared papers, 2020–2023 · strength 0.42
  24. Giuseppe Malleo · 3 shared papers, 2021–2023 · strength 0.39
  25. Claudio Bassi · 3 shared papers, 2021–2023 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.